Sign in Subscribe
AstraZeneca PLC

AstraZeneca Reiterates Full-Year Guidance for 2025 Amid Robust Q2 and Half-Year Results

Strategic Insights

— 1 min read

AstraZeneca's robust second-quarter and half-year results have reinforced the pharmaceutical group's full-year guidance for 2025. The company's strong revenue growth, core earnings per share, and late-stage trial successes across its research and development pipeline have contributed to its confidence in meeting its financial targets. With a series of significant regulatory approvals, including treatments for blood cancers, lung cancer, and asthma, AstraZeneca is well-positioned for continued growth.

Key Takeaways:

  • AstraZeneca reported total revenue of $14.46 billion for the second quarter, up 12% at actual exchange rates, driven by double-digit growth in oncology and biopharmaceuticals.
  • Core earnings per share for the quarter rose 10% to $2.17, while reported earnings per share were $1.58, up 27%.
  • The company declared an interim dividend of $1.03, an increase of 3%.
  • AstraZeneca secured 19 regulatory approvals in major markets, including treatments for blood cancers, lung cancer, and asthma.
  • The company has reaffirmed its outlook for the full year, expecting total revenue to rise by a high single-digit percentage and core earnings per share to increase by a low double-digit percentage at constant exchange rates.
  • AstraZeneca has acquired EsoBiotec, a biotechnology group focused on in vivo cell therapies, in a deal worth up to $1 billion.
  • The company has entered a research partnership with CSPC Pharmaceuticals Group in China, with potential milestone payments of up to $1.62 billion for development and $3.6 billion for sales.

Statistics:

  • Total revenue for the second quarter: $14.46 billion (up 12% at actual exchange rates)
  • Core earnings per share for the quarter: $2.17 (up 10%)
  • Reported earnings per share for the quarter: $1.58 (up 27%)
  • Interim dividend: $1.03 (increase of 3%)
  • Regulatory approvals: 19
  • Late-stage trial successes: 12
  • Business deal with EsoBiotec: up to $1 billion
  • Research partnership with CSPC Pharmaceuticals Group: potential milestone payments of up to $1.62 billion for development and $3.6 billion for sales

Sources:

  • AstraZeneca PLC's (LSE:AZN) official website, as reported in the article.

Note: The article does not provide explicit sources; the only provided link is to an external website for the full-text of the article. As such, the source listed above is the only information available.

Read more